1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Jinxin Fertility Group Limited

Jinxin Fertility Group Limited

JXFGF
Jinxin Fertility Group LimitedUS flagOther OTC
0.29
USD
- -
- -
752.38MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.15
0.28
0.39
0.75
0.59
0.74
0.95
1.04
1.05
0.97
Basic EPS, GAAP
0.04
0.04
0.07
0.19
0.1
0.14
0.05
0.13
0.11
-0.36
Free Cash Flow per Basic Share
0.04
0.01
0.14
0.08
-0.01
0.11
-0.17
0.19
0.14
0.12
Dividend per Share
- -
0.03
0.05
0.15
0.06
- -
0.06
- -
0.06
- -
Book Value per Share
0.03
0.29
- -
- -
0.32
0.44
0.45
0.54
0.64
0.24
Tangible Book Value per Share
0.04
0.21
0.03
1.44
1.12
0.33
-0.38
0.18
0.24
0.21
Basic Weighted Avg Shares
2,381
2,381
2,381
2,199
2,400
2,478
2,496
2,676
2,681
2,742
Sales/Revenue/Turnover
346
663
922
1,648
1,426
1,839
2,364
2,789
2,812
2,649
Operating Margin (%)
30.61
35.7
28.71
28.56
17.21
20.57
10.72
18.4
16.14
7.86
Depreciation Expense
14
35
42
113
130
169
260
285
276
345
Net Income, GAAP
88
99
167
410
252
340
121
345
283
-976
Effective Tax Rate (%)
5.21
17.81
23.31
23.22
25.39
22.76
23.57
25.26
30.22
- -
Profit Margin (%)
25.28
14.9
18.07
24.85
17.64
18.48
5.12
12.36
10.07
-36.85
Working Capital
-448
331
59
2,990
2,097
1,472
-860
-347
-1,030
-192
LT Debt
- -
- -
- -
153
354
1,990
2,447
1,729
1,274
2,173
Total Equity
101
1,362
4,500
7,642
7,462
8,753
8,735
10,187
10,354
9,199
Return on Invested Capital (%)
- -
25.65
6.77
5.79
2.31
3.09
1.62
2.97
2.46
- -
Return on Capital (%)
- -
-0.16
19.24
186.57
30.66
14.42
4.08
8.49
7.84
- -
Return on Common Equity (%)
- -
26.4
48.4
283,476.12
65.82
36.43
10.91
26.85
17.92
-82.63

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.84%
-11.16%
Free Cash Flow
- -
-477.67%
-11.56%
Net Income, GAAP
- -
-61.47%
-444.81%
Sales/Revenue/Turnover
- -
14.1%
-5.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2,789
2024
- -
- -
- -
- -
2,812
2025
- -
- -
- -
- -
2,649

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.13
2024
- -
- -
- -
- -
0.11
2025
- -
- -
- -
- -
-0.36

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
0.06
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Yang Dong
Full Time Employees
3,198
Sector
Healthcare
Industry
Medical - Care Facilities
Address
No. 301, North Jingsha Road Chengdu People's Republic of China
IPO Date
Jun 25, 2021
Website
jxr-fertility.com
Similar Companies
LNA Santé S.A. (0OR2.L)
N G Industries Ltd. (NGIND.BO)
Dental Patient Care America, Inc. (DPAT)
The Amacore Group, Inc. (ACGI)
Delta Drone S.A. (ALDBY.PA)
Ramsay Health Care Limited (RMYHY)
Business
Jinxin Fertility Group Limited, an investment holding entity, delivers advanced assisted reproductive services across mainland China and the United States. The company specializes in comprehensive treatment options, including artificial insemination, utilizing either partner or donor sperm, alongside advanced in vitro fertilization technologies such as conventional IVF and IVF with intracytoplasmic sperm injection. Beyond core fertility treatments, the group offers a suite of complementary services designed to support the entire patient journey, encompassing nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Furthermore, Jinxin provides broader medical care including obstetrics, gynecology, and pediatrics, as well as managing ambulatory surgery centers and offering various ancillary medical services. The company is also involved in cutting-edge molecular genetics services, pre-implantation genetic screening, and cryopreservation techniques. Its operations extend to providing management solutions for fertility clinics and hospitals, alongside limited activities in property investment and real estate development. Established in 2018, Jinxin Fertility Group Limited maintains its corporate headquarters in Chengdu, China. The company has recently expanded its footprint with new facilities in Shenzhen and a satellite center in Beverly Hills, while strategically partnering with entities like Warburg Pincus to explore future acquisition opportunities. In 2025, the company introduced a new share scheme to enhance operational capabilities and align management incentives.